dc.contributor.author
Mahdizadeh, Shadi
dc.contributor.author
Karimi, Gholamreza
dc.contributor.author
Behravan, Javad
dc.contributor.author
Arabzadeh, Sepideh
dc.contributor.author
Lage, Hermann
dc.contributor.author
Kalalinia, Fatemeh
dc.date.accessioned
2018-06-08T04:15:18Z
dc.date.available
2016-08-10T11:41:07.854Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/16899
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-21080
dc.description.abstract
Background Crocin, one of the main constituents of saffron extract, has
numerous biological effects such as anti-cancer effects. Multidrug resistance-
associated proteins 1 and 2 (MRP1 and MRP2) are important elements in the
failure of cancer chemotherapy. In this study we aimed to evaluate the effects
of crocin on MRP1 and MRP2 expression and function in human ovarian cancer
cell line A2780 and its cisplatin-resistant derivative A2780/RCIS cells.
Methods The cytotoxicity of crocin was assessed by the MTT assay. The effects
of crocin on the MRP1 and MRP2 mRNA expression and function were assessed by
real-time RT-PCR and MTT assays, respectively. Results Our study indicated
that crocin reduced cell proliferation in a dose-dependent manner in which the
reduction in proliferation rate was more noticeable in the A2780 cell line
compared to A2780/RCIS. Crocin reduced MRP1 and MRP2 gene expression at the
mRNA level in A2780/RCIS cells. It increased doxorubicin cytotoxicity on the
resistant A2780/RCIS cells in comparison with the drug-sensitive A2780 cells.
Conclusion Totally, these results indicated that crocin could suppress drug
resistance via down regulation of MRP transporters in the human ovarian cancer
resistant cell line.
en
dc.rights.uri
http://creativecommons.org/licenses/by/4.0/
dc.subject
Multidrug resistance
dc.subject.ddc
500 Naturwissenschaften und Mathematik::570 Biowissenschaften; Biologie
dc.title
Crocin suppresses multidrug resistance in MRP overexpressing ovarian cancer
cell line
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation
DARU Journal of Pharmaceutical Sciences. - 24 (2016), Artikel Nr. 17
dcterms.bibliographicCitation.doi
10.1186/s40199-016-0155-8
dcterms.bibliographicCitation.url
http://darujps.biomedcentral.com/articles/10.1186/s40199-016-0155-8
refubium.affiliation
Charité - Universitätsmedizin Berlin
de
refubium.mycore.fudocsId
FUDOCS_document_000000025063
refubium.note.author
Der Artikel wurde in einer Open-Access-Zeitschrift publiziert.
refubium.resourceType.isindependentpub
no
refubium.mycore.derivateId
FUDOCS_derivate_000000006807
dcterms.accessRights.openaire
open access